![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic. Enzymes are applied therapeutically in only a handful of applications, including for wrinkle treatment (Botox), cancer (Asparaginase), and cystic fibrosis (DNase).
Lead Product(s): Enzyme Therapy
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Kizoo Technology Capital
Deal Size: $8.4 million Upfront Cash: Undisclosed
Deal Type: Financing March 17, 2022